secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001193125-25-247410
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics priced 11.4M-share offering at $22/sh for ~$251M gross proceeds
--------------------------------------------------------------------------------

- Offering of 11,425,000 shares at $22.00/share; underwriters have 30-day option for up to 1,713,750 additional shares.
- Gross proceeds of ~$251.35M before underwriting discounts and expenses; closing expected October 23, 2025.
- Net proceeds combined with existing cash, $70M Kissei upfront (Q4 2025), $55M DRI payment, $115M potential DRI milestones, and $30M term loan to fund operations.
- Company assumes revenue from veligrotug and VRDN-003 if approved on anticipated timelines to extend cash runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525247410/0001193125-25-247410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525247410/d27166d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-247410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer